Strategic Collaborators
Vie Ventures believes participation in life sciences venture capital is critical to translating discovery research into development towards regulatory approval to achieve our mission of advancing innovative therapeutics for patients.
Our strategic collaborators have funded billions of dollars of discovery research – and Vie Ventures strives to make sure that investment is translated into life-changing therapies and cures for patients through the venture capital process.
How We Partner Differently
Collaboration with leading disease philanthropies
Collaboration with leading disease philanthropies
Vie Ventures provides a purpose-fit way for these organizations to participate by investing alongside other stakeholders in development. Through partnering with our strategic collaborators, Vie Ventures can amplify the voice of the patient, which we believe leads to better outcomes.
Diligence and execution
Diligence and execution
Our deep network of industry participants and a sophisticated investor base makes us a valuable partner in choosing right investment opportunities then amassing the human and financial capital required for success.
Clinician and scientific network
Clinician and scientific network
Disease-focused philanthropies are very well connected with researchers, clinicians and patient groups, which are highly sought after by biotech companies and their investors. Vie Ventures works with strategic collaborators to actively connect these constituents.
Advocacy, regulatory, & reimbursement
Advocacy, regulatory, & reimbursement
Vie Ventures is well-versed in the principles of drug development as well as the complex issues that determine how quickly and successfully a new therapy can reach patients. Vie Ventures works with our companies and strategic collaborators to knock down barriers to new therapies reaching patients.
Other ecosystem access & visibility
Other ecosystem access & visibility
Beyond financial capital, Vie Ventures is a valuable partner for companies and their venture capital syndicates in delivering life-changing therapies and cures for patients.
Advancing Innovative Therapeutics
Biopharmaceutical companies need investors who can bring more than just capital: they can benefit from partners with expertise within discrete disease-focused ecosystems. In addition, we believe that cross-collaboration across multiple disease ecosystems has the potential to accelerate our mission and expand therapeutic possibilities, which is particularly true within autoimmune diseases.
By engaging strategic collaborators across the biotech ecosystem – disease-focused philanthropies, research foundations, and biopharmaceutical companies – we can drive success and leverage our collective resources towards a common, transformative goal.
